Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$9.40 and traded as low as C$9.21. Fennec Pharmaceuticals shares last traded at C$9.21, with a volume of 201 shares changing hands.
Fennec Pharmaceuticals Trading Down 7.9 %
The firm has a market capitalization of C$163.53 million, a price-to-earnings ratio of -143.65 and a beta of 0.25. The business's 50-day moving average price is C$9.41 and its 200 day moving average price is C$8.11. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17.
Insider Buying and Selling
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 7,569 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of C$9.71, for a total transaction of C$73,503.54. Insiders have sold 21,186 shares of company stock valued at $196,017 in the last quarter. Company insiders own 16.20% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
